HIV

HIV Pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges
abstract Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and buprenorphine decrease HIV acquisition. Between November, 2016 - July, 2017, we surveyed persons (N=200) at a drug detoxification center to assess their interest in PrEP and in buprenorphine, and to examine factors associated with such interests.
Sabrina A Assoumou, Samantha M Paniagua, Priscilla Gonzalez, Jianing Wang, Curt G Beckwith, Laura F White, Jessica L Taylor, Kristen Coogan, Jeffrey H Samet, Benjamin P Linas
Cite DOI Link
Rapid versus laboratory-based testing for HIV and hepatitis C at a drug detoxification treatment center: a randomized trial
abstract Background A health department survey revealed nearly half employ laboratory-based HIV and HCV testing (LBT) over rapid testing (RT) in nonhospital settings such as drug detoxification centers. LBT has higher sensitivity for acute HIV infection compared to RT but LBT is not point of care and may result in fewer diagnoses due to loss to follow-up before result delivery.
Sabrina A Assoumou, Samantha M Paniagua, Benjamin P Linas, Jianing Wang, Jeffrey H Samet, Jonathan Hall, Laura F White, Curt G Beckwith
Cite DOI Link